Teva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. APGE
5. USO
6. MU
7. HOOD
8. DFTX
9. GOOGL
10. ABBV

Go back to Teva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia

Teva Pharma (TEVA) PT Raised to $18 at BofA Securities

May 9, 2024 6:16 AM EDT

BofA Securities analyst Jason Gerberry raised the price target on Teva Pharma (NYSE: TEVA) to $18.00 (from $16.00) while maintaining a Buy rating.

The analyst comments "We raise our TEVA PO to $18 (from $16) following positive Phase 3 SOLARIS trial
update for the Olanzapine LAI [long-acting... More